Compounded GLP-1 medications in 2026: what changed and what to verify
Compounded semaglutide and tirzepatide did not become generic Ozempic, Wegovy, Mounjaro, or Zepbound. In 2026, FDA policy sharpened the difference between individualized compounding and mass-marketed copies.
The short answer: compounded semaglutide and tirzepatide remain prescription drugs made under limited compounding pathways; they are not FDA-approved generics or interchangeable copies of the branded products. In 2026, the FDA emphasized that compounders cannot routinely make products that are essentially copies of commercially available drugs and announced enforcement attention on mass-marketed, non-approved GLP-1 products.12
That does not mean every lawful prescription for a compounded GLP-1 disappeared. It means the reason for compounding, the patient-specific prescription, the exact ingredient, and the source matter more than a program’s marketing name.
What changed in 2026
During shortages, federal policy gave compounders more room to prepare copies of drugs that were not commercially available. As supply stabilized, that shortage-based rationale narrowed. The FDA’s April 2026 clarification returned the focus to the standing conditions in sections 503A and 503B of federal law.1
Under 503A, qualifying compounding is generally tied to a prescription for an identified individual patient, and a compounder may not regularly make inordinate amounts of products that are essentially copies of commercially available drugs. A prescriber can identify a change that produces a significant difference for a particular patient, but “personalized” on a sales page is not the same as that documented clinical determination.
Under 503B, registered outsourcing facilities may compound certain drugs without patient-specific prescriptions, but they operate under a different set of conditions and cannot make products that are essentially copies of approved drugs except in defined circumstances. Neither label means the finished compounded drug is FDA-approved.
| Term | What it establishes | What it does not establish |
|---|---|---|
| FDA-approved GLP-1 drug | FDA reviewed a specific product, indication, manufacturing process, and labeling. | Approval of every use, dose, or source discussed by a clinic. |
| 503A compounding | A pathway for qualifying pharmacy or physician compounding, generally for an identified patient. | FDA approval or permission to mass-produce a routine copy. |
| 503B outsourcing facility | A facility registered with FDA that compounds under the outsourcing-facility framework. | FDA approval of each finished drug or the clinic administering it. |
| Generic | An FDA-approved product evaluated through an abbreviated application. | A synonym for a compounded version of a branded drug. |
The exact product name matters
Ask whether the prescription is for semaglutide base or a salt form such as semaglutide sodium or semaglutide acetate. FDA says the salt forms are different active ingredients from the base form used in approved semaglutide drugs and that it is not aware of a basis for their use that would meet the relevant federal compounding conditions.3
Also ask whether other ingredients are mixed into the vial. Vitamin B12 or another additive does not automatically turn an otherwise substitutable copy into a clinically different product. FDA’s 2026 explanation says it may still view a semaglutide-plus-B12 product as essentially a copy when the added ingredient does not produce a difference prescribed as significant for the identified patient.1
Why concentration and units deserve their own check
Approved injectable semaglutide products use standardized presentations. Compounded products may arrive in multi-dose vials or syringes and may have different concentrations. FDA has received reports of patients taking five to 20 times the intended dose after confusion among milligrams, milliliters, and syringe “units”; some people required hospital care.3
Before the first dose, the written instructions should let you connect four values without mental arithmetic: prescribed milligrams, concentration in milligrams per milliliter, volume to draw, and the matching mark on the supplied syringe. If instructions only say “units,” ask for the milligram dose and concentration too.
Seven questions before enrolling
- Name the drug precisely. Ask for the active ingredient, form, strength, concentration, and every added ingredient.
- Identify why it is compounded. Ask what patient-specific need cannot be met by an available FDA-approved product and where that determination is documented.
- Name the compounder. Get the pharmacy or outsourcing facility's legal name and state, then ask whether the prescription is filled under 503A or supplied by a 503B facility.
- Trace the prescription. Confirm who evaluates you, who prescribes, how follow-up works, and how you reach that clinical team with a dosing question.
- Rehearse the measurement. Match milligrams, concentration, milliliters, syringe size, and the correct syringe line before leaving with a vial.
- Read the marketing literally. Treat claims such as generic, same as, or clinically proven as claims requiring product-specific support; FDA expressly addressed those comparisons in 2026. 2
- Plan continuity. Ask what happens if the compounder, formulation, availability, or program price changes after enrollment.
A practical decision framework
Program pricing deserves the same specificity as the prescription. Ask whether the advertised amount includes clinical visits, the medication at every dose level, supplies, shipping, laboratory work, and follow-up. Find out whether a higher concentration or dose changes the monthly price and whether unused prepaid months are refundable. A low first-month figure can describe an intake offer rather than the ongoing cost.
Continuity is also clinical, not only financial. Ask how the program handles a late shipment, temperature excursion, damaged vial, missed dose, side effect, or transition to an FDA-approved product. Confirm whether your regular clinicians can receive the medication list and treatment record. Those operational details help distinguish an ongoing care program from a product subscription.
Start with the clinical evaluation, not the subscription price. Then identify the exact FDA-approved or compounded product, establish why that route was chosen, trace the dispensing source, and make the dose measurable. A program that can answer those points in writing gives you something concrete to compare.
On Treomark, use the GLP-1 and weight-management searches to find locations that publish the service. Open each linked source, identify the named clinician, and check that person’s license record. The service listing tells you where a program is offered; the questions above tell you what the program actually contains.
Sources
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA's April 2026 explanation of 503A and 503B conditions and the essentially-a-copy analysis. Accessed .
- U.S. Food and Drug Administration. FDA intends to take action against non-FDA-approved GLP-1 drugs. FDA's February 2026 enforcement statement on mass-marketed compounded GLP-1 products and promotional claims. Accessed .
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Describes variable concentrations, unit-conversion errors, semaglutide salt forms, and reported overdoses. Accessed .
- U.S. Food and Drug Administration. Human drug compounding. FDA overview of compounded drugs and the 503A and 503B frameworks. Accessed .